Nipocalimab (say it a couple of times) is a FcRn (neonatal Fc receptor) inhibitor. In short promotes degradation of IgG incl autoantibodies (and investigated in myasthenia). Prof Taylor presents that it might work in CCP high titer RA at #ACR23. #ACRambassador @ACRheum https://t.co/DqlsOv7AVI

B cell signalling reduction to treat #RA? Telitacicept RCT showed #efficacy in active RA w MTX -maybe blunted high responses but no active comparator, only #PBO so difficult to compare to current Rx and only from 1 country China. Past bDMARDs not reported L20 @RheumNow @ACRheum

As per #ACR23 ABST0433, what % of RA patients on US Medicare are on a DMARD within 1y of diagnosis? I'm not talking your choice of b/tsDMARD. I'm talking any cs/b/tsDMARD of any sort. Hear from @JihaRheum to skip to the answer: https://t.co/lI2M20JWKC Truly stunning. @RheumNow

Sex bias in RA: time to stop blaming hormones? https://t.co/uPq87r4Ndv https://t.co/Yleu2LDV3g

• Sex bias in RA: time to stop blaming hormones? | RheumNow

Taylor et al. Novel blood assay for sero+ and sero- RA. Differentiates well from other diseases. May be very valuable for sero- RA diagnosis = sensitivity 83.7%, +LR 21.46, and -LR 0.17. Needs validation. Abstr#2586 #ACR23 @RheumNow https://t.co/jw41F8YohE https://t.co/kXi3km0b07

Last abstract of #ACR23 was #ACRBest Plasma cfDNA signatures (synovial mapped) to identify RA vs OA, other inflamm arthritis Great performance, even with seroneg RA A blood test to: diagnose ?phenotype ?identify best b/tsDMARD Could be massive Peter Taylor ABST2586 @RheumNow https://t.co/tJX2jXV0Oe

#ACRbest Yrin Preview @ACRheum J Bathon Take home Symptomatic #Rx of ACPA+ people WITH #DMARD is too late to alter risk of #RA when drug is d/c AI to read joint erosions on X-ray May be ‘too little too late’ #Steroids in #RA increase #MACE even after d/c #ACR23 @RheumNow

#ACR23 Yr in Preview J Bathon Shared decision making w tradeoffs showed sex differences for concerns & preferences in #RA present dependent on how you ask the questions Unmet needs (I think 🤔) biomarkers of flare for #inflammatory #arthritis Rx select’n/retention @RheumNow

Watch: Assessment and Treatment of Cardiovascular Risks in Rheumatoid Arthritis Dr. Antoni Chan discusses abstract 0387 and abstract 0391 presented at #ACR23 https://t.co/avnarOGZui https://t.co/4CeAumv31b

• Assessment and Treatment of Cardiovascular Risks in Rheumatoid Arthritis | Rheu…

Telitacicept a recombinant fusion protein targeting, neutralizing BLyS and APRIL, phase 3 study in RA MTX-IR at 24 wk, ACR20 (60% vs 27% PBO), ACR50 (21% vs 6% PBO), reduced DAS28-ESR, no radiographic progression, Wang L Abst#L20 #ACR23 #ACRBest @RheumNow https://t.co/nuvizqQZsR https://t.co/PRtlea3AqU